Current Report Filing (8-k)
November 15 2021 - 5:10PM
Edgar (US Regulatory)
0001213660
false
CN
0001213660
2021-11-15
2021-11-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 15, 2021
BIMI International Medical Inc.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-34890
|
|
02-0563302
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
9th
Floor, Building 2, Chongqing Corporation Avenue,
Yuzhong District, Chongqing, P. R. China
|
|
116000
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (8604) 1182209211
Not Applicable
|
(Former name or former address, if changed since last report)
|
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common stock,
$0.001 par value
|
|
BIMI
|
|
The Nasdaq
Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On November 15, 2021, the Registrant reported
its results of operations for the quarterly period ended September 30, 2021. A copy of the press release issued by the Registrant in this
connection is furnished herewith as Exhibit 99.1.
The information in this Item in this Current Report
on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation
language in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: November 15, 2021
|
BIMI International Medical Inc.
|
|
|
|
By:
|
/s/ Tiewei Song
|
|
Name:
|
Tiewei Song
|
|
Title:
|
Chief Executive Officer
|
2
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Apr 2023 to Apr 2024